Citius Oncology, Inc. (CTOR) - 10-Q Summary
Business Context and Reporting Period
Citius Oncology, Inc. is a specialty biopharmaceutical company focused on the commercialization of LYMPHIR (denileukin diftitox), an immunotherapy for cutaneous T-cell lymphoma (CTCL). This report covers the quarterly period ended June 30, 2026. The Company is a smaller reporting company and an emerging growth company. Revenue generation commenced in December 2025 following the commercial launch of LYMPHIR.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Nine Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $1,493,788 | $7,105,197 |
| Gross Profit | $1,001,945 (67% margin) | $5,495,268 (77% margin) |
| Net Loss | $(8,923,846) | $(41,067,610) |
| Cash and Cash Equivalents | $16,563,705 (as of June 30, 2026) | |
| Working Capital | Negative $16.1 million | |
| Total Debt (Notes Payable) | $6,410,161 (net of deferred costs) | |
| Accumulated Deficit | $(105,107,566) |
Material Changes vs. Prior Period
- Revenue Growth: The Company generated $7.1 million in revenue for the nine months ended June 30, 2026, compared to $0 in the prior year period, driven by the December 2025 launch of LYMPHIR.
- Operating Expenses: Total operating expenses increased significantly to $48.1 million (nine months 2026) from $18.8 million (nine months 2025). This increase was primarily due to a $19.7 million contract cancellation fee recorded in March 2026 following the termination of a contract manufacturing organization (CMO) agreement due to payment breaches.
- Amortization: Amortization of in-process research and development (IPR&D) began in December 2025, resulting in $4.0 million of expense for the nine months ended June 30, 2026, compared to $0 in the prior year.
- Financing Activity: The Company raised capital through a May 2026 warrant inducement transaction ($9.7 million net proceeds) and a term loan agreement ($10.0 million funded in May 2026).
Outlook, Risks, and Contingencies
- Going Concern: The Company's independent auditors have included an explanatory paragraph stating there is substantial doubt about the Company's ability to continue as a going concern. Management expects funds to last through November 2026 but will require additional capital thereafter.
- Debt Obligations: A new term loan agreement allows for up to $25.0 million, with $10.0 million funded. Additional tranches ($7.0M and $8.0M) are contingent on achieving specific net revenue and liquidity milestones. The loan bears interest at the greater of Prime + 6% or 12.75% and is secured by substantially all Company assets.
- Manufacturing: Following the termination of the previous CMO, the Company entered a letter of intent with a new CMO in June 2026. Management anticipates no interruption in commercial supply.
- Nasdaq Compliance: The Company received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to a minimum bid price below $1.00 for 30 consecutive days. It has until October 19, 2026, to regain compliance.
- License Payments: Significant milestone payments remain due to Dr. Reddy's ($15.65 million) and Eisai (approximately $6.3 million in unpaid invoices).
Investor Verification Checklist
- Cash Runway: Verify the timeline for raising additional capital required to sustain operations beyond November 2026.
- Debt Milestones: Monitor the achievement of revenue and liquidity milestones required to access the remaining $15.0 million under the term loan agreement.
- Manufacturing Stability: Confirm the execution of the definitive master services agreement with the new CMO and the absence of supply chain disruptions.
- Nasdaq Status: Track the stock price to ensure compliance with the $1.00 minimum bid price requirement by the October 19, 2026 deadline.
- Revenue Sustainability: Assess the growth trajectory of LYMPHIR sales to determine if revenue can cover the high fixed costs, including IPR&D amortization and debt service.